<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484729</url>
  </required_header>
  <id_info>
    <org_study_id>D6400C00001</org_study_id>
    <secondary_id>2015-000877-11</secondary_id>
    <nct_id>NCT02484729</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males</brief_title>
  <official_title>A Phase I, Randomized, Single-blind, Placebo-controlled Study to Access the Safety, Tolerability and Pharmacokinetics of AZD9977 Following Single Ascending Dose Administration to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a randomized, single-blind, placebo-controlled first-in-human study in
      healthy male subjects to assess the safety, tolerability and pharmacokinetics of single
      ascending doses of AZD9977. In Part B of this study the regional absorption of AZD9977 along
      the gastro-intestinal tract will be investigated using the IntelliCap® system in a
      non-randomized, open-label, fixed-sequence design. The study will be performed at a single
      study centre.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized, single-blind, placebo-controlled first-in-human study in
      healthy male subjects to assess the safety, tolerability and pharmacokinetics of single
      ascending doses of AZD9977. In Part B of this study the regional absorption of AZD9977 along
      the gastro-intestinal tract will be investigated using the IntelliCap® system in a
      non-randomized, open-label, fixed-sequence design with oral solution as reference. The study
      will be performed at a single study centre.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events</measure>
    <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
    <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Pulse Rate</measure>
    <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
    <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Trends in 12-lead Electrocardiograms</measure>
    <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
    <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD9977 by Number of Participants With Clinically Significant Trends in Cardiac Telemetry</measure>
    <time_frame>For up to 4 days, i.e. on the day before each dosing and for 24 hours after each dosing</time_frame>
    <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD9977 by Assessing the Number of Subjects With Adverse Events</measure>
    <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
    <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Blood Pressure</measure>
    <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
    <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Hematology</measure>
    <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
    <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Clinical Chemistry</measure>
    <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
    <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Urinalysis</measure>
    <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
    <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity.</measure>
    <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
    <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte concentrationAUC(0-t)</measure>
    <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
    <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Concentration (Cmax)</measure>
    <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
    <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (t Max)</measure>
    <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
    <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz)</measure>
    <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
    <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F)</measure>
    <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
    <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
    <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount of Unchanged Drug Excreted Into Urine [Ae (0-48)]</measure>
    <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
    <description>To assess urine pharmacokinetic parameters following single ascending doses of AZD9977</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction Excreted Unchanged in Urine[Fe (0-48)]</measure>
    <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
    <description>To assess percentage of the total drug excreted in the urine that was unchanged following single ascending doses of AZD9977</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance of Drug From Plasma [CLR (0-48)]</measure>
    <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
    <description>To assess urine pharmacokinetic parameters following single ascending doses of AZD9977</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Safety</condition>
  <condition>Tolerability</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>AZD9977 oral suspension, single doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A up to 10 cohorts with single ascending doses with AZD9977 as oral suspension. In Part B AZD9977 as oral suspension in IntelliCap® capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, oral suspension, single doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Part A up to 10 cohorts with single doses with matching placebo to AZD9977</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD9977, oral solution, single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part B, of oral solution of AZD9977 will be used as reference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9977, oral suspension</intervention_name>
    <description>Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)</description>
    <arm_group_label>AZD9977 oral suspension, single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, oral suspension</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo, oral suspension, single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9977, oral solution</intervention_name>
    <description>AZD9977, single dose of oral solution in Part B as reference</description>
    <arm_group_label>AZD9977, oral solution, single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated written informed consent prior to any study specific
             procedures.

          2. Healthy male subjects aged 18 to 50 years with suitable veins for cannulation or
             repeated venipuncture.

          3. Male subjects have to comply with the restrictions for sexual activity provided to
             them.

          4. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50
             kg and no more than 100 kg inclusive.

          5. Optional: Provision of signed and dated written informed consent for genetic research.

             If a subject declines to participate in the genetic component of the study, there will
             be no penalty or loss of benefit to the subject. The subject will not be excluded from
             other aspects of the study described in this protocol.

          6. Able to understand, read and speak the English language.

        Exclusion Criteria:

          1. History of any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the potential subject at risk because of participation in
             the study, or influences the results or the potential subject's ability to participate
             in the study.

          2. History or presence of GI, hepatic or renal disease, or any other condition known to
             interfere with absorption, distribution, metabolism, or excretion of drugs.

          3. Any clinically significant illness, medical/surgical procedure, or trauma within 4
             weeks of dosing in Part A or the first dose of AZD9977 in Part B.

          4. Any clinically significant abnormalities in hematology, clinical chemistry or
             urinalysis results, as judged by the investigator.

          5. Any positive result at screening for serum hepatitis B surface antigen (HBsAg),
             hepatitis C antibody, and human immunodeficiency virus (HIV) antibodies.

          6. Abnormal findings in vital signs, after 10 minutes resting in the supine position,
             defined as any of the following:

               -  Systolic blood pressure (SBP) &lt; 90 mmHg or ≥ 140 mmHg

               -  Diastolic blood pressure (DBP) &lt; 50 mmHg or ≥ 90 mmHg

               -  Pulse &lt; 45 or &gt; 90 bpm

          7. Any clinically important abnormalities in rhythm, conduction or morphology of the
             electrocardiogram (ECG) at screening or pre-dose, as considered by the investigator.

          8. Prolonged QTcF &gt; 450 ms or family history of long QT syndrome.

          9. PR (PQ) interval shortening &lt; 120 ms. PR &gt; 110 ms but &lt; 120 ms is acceptable if there
             is no evidence of ventricular pre-excitation.

         10. PR (PQ) interval prolongation &gt; 240ms; intermittent second or third degree
             atrioventricular (AV) block, or AV dissociation.

             Wenckebach block while asleep is not exclusive.

         11. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle
             branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS &gt; 110 ms.

             QRS &gt; 110 ms but &lt; 115 ms are acceptable if there is no evidence of ventricular
             hypertrophy or pre-excitation.

         12. Serum potassium higher than 5.0 mmol/L at screening or admission to the study center
             (Day -1).

         13. Known or suspected history of drug abuse as judged by the investigator.

         14. Current smokers or those who have smoked or used nicotine products within the previous
             3 months.

         15. History of alcohol abuse or excessive intake of alcohol as judged by the investigator.

         16. Positive screen for drugs of abuse, alcohol or cotinine at screening or admission to
             the study center.

         17. History of severe allergy/hypersensitivity or ongoing clinically important
             allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity
             to drugs with a similar chemical structure or class to AZD9977.

         18. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea and
             chocolate) as judged by the investigator.

         19. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks
             prior to dosing in Part A or the first dose of AZD9977 in Part B.

         20. Use of any prescribed or non-prescribed medication including antacids, analgesics
             (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of
             20 to 600 times the recommended daily dose) and minerals during 2 weeks prior to
             dosing in Part A or the first dose of AZD9977 in Part B, or longer if the medication
             has a long half-life.

         21. Plasma donation within one month of screening or any blood donation/blood loss &gt; 500
             mL during the 3 months prior to screening.

         22. Has received another new chemical entity (defined as a compound which has not been
             approved for marketing) within 3 months of dosing in Part A or the first dose of
             AZD9977 in Part B in this study. The period of exclusion begins 3 months after the
             final dose or one month after the last visit whichever is the longest.

             Note: Subjects consented and screened, but not randomized in this study or a previous
             phase I study, are not excluded.

         23. Involvement of any AstraZeneca or study site employee or their close relatives.

         24. Judgment by the investigator that the subject should not participate in the study if
             they have any ongoing or recent (i.e., during the screening period) minor medical
             complaints that may interfere with the interpretation of study data or are considered
             unlikely to comply with study procedures, restrictions and requirements.

         25. Subjects who are vegans or have medical dietary restrictions (vegetarians may be
             included in the study).

         26. Subjects who cannot communicate reliably with the investigator.

         27. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship,
             trusteeship, or committed to an institution by governmental or juridical order.

             In addition, any of the following is regarded as a criterion for exclusion from the
             genetic research:

         28. Previous bone marrow transplant.

         29. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the
             genetic sample collection.

             Criteria applicable to Part B only:

         30. Subjects with pacemakers or other implanted electro-medical devices.

         31. Subjects with swallowing disorders.

         32. Subjects with pre-planned MRI examination.

         33. Subjects not willing to have an abdominal X-ray performed if the IntelliCap® capsule
             has not been retrieved within one week after ingestion.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muna Albayaty, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Early Phase Clinical Unit London, Level 7, Northwick Park Hospital, Watford Road, Harrow, Middlesex HA1 3UJ, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <results_first_submitted>November 25, 2016</results_first_submitted>
  <results_first_submitted_qc>February 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2017</results_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD9977</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>First-in-human</keyword>
  <keyword>Single Ascending Dose</keyword>
  <keyword>Regional absorption</keyword>
  <keyword>Healthy male subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at PAREXEL International, Early Phase Clinical Unit London, United Kingdom.</recruitment_details>
      <pre_assignment_details>In this study, 196 subjects were screened out of which 70 subjects were randomized. The study was conducted in two parts (Parts A and B). Part A-eight cohorts of 8 subjects, randomized in 6:2 (AZD9977: placebo) and Part B -1 cohort of 8 subjects who received a single dose of AZD9977, on 2 occasions separated by washout period of 7 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A- Placebo</title>
          <description>Subjects received matching placebo under fasted conditions</description>
        </group>
        <group group_id="P2">
          <title>Part A - 5 mg AZD9977</title>
          <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="P3">
          <title>Part A - 25 mg AZD9977</title>
          <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="P4">
          <title>Part A - 100 mg AZD9977</title>
          <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="P5">
          <title>Part A - 200 mg AZD9977</title>
          <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="P6">
          <title>Part A - 400 mg AZD9977</title>
          <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="P7">
          <title>Part A - 800 mg AZD9977</title>
          <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="P8">
          <title>Part A - 800 mg AZD9977 (Split Doses)</title>
          <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
        </group>
        <group group_id="P9">
          <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
          <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
        </group>
        <group group_id="P10">
          <title>Part B</title>
          <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failure of IntelliCap Error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A- Placebo</title>
          <description>Subjects received matching placebo under fasted conditions</description>
        </group>
        <group group_id="B2">
          <title>Part A - 5 mg AZD9977</title>
          <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="B3">
          <title>Part A - 25 mg AZD9977</title>
          <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="B4">
          <title>Part A - 100 mg AZD9977</title>
          <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="B5">
          <title>Part A - 200 mg AZD9977</title>
          <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="B6">
          <title>Part A - 400 mg AZD9977</title>
          <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="B7">
          <title>Part A - 800 mg AZD9977</title>
          <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="B8">
          <title>Part A - 800 mg AZD9977 (Split Doses)</title>
          <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
        </group>
        <group group_id="B9">
          <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
          <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
        </group>
        <group group_id="B10">
          <title>Part B</title>
          <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="8"/>
            <count group_id="B11" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="6"/>
                    <measurement group_id="B2" value="32" spread="11"/>
                    <measurement group_id="B3" value="30" spread="9"/>
                    <measurement group_id="B4" value="36" spread="10"/>
                    <measurement group_id="B5" value="32" spread="10"/>
                    <measurement group_id="B6" value="33" spread="9"/>
                    <measurement group_id="B7" value="30" spread="6"/>
                    <measurement group_id="B8" value="32" spread="8"/>
                    <measurement group_id="B9" value="38" spread="11"/>
                    <measurement group_id="B10" value="35" spread="9"/>
                    <measurement group_id="B11" value="33" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events</title>
        <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
        <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
        <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A- Placebo</title>
            <description>Subjects received matching placebo under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O10">
            <title>Part B</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events</title>
          <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
          <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="20.0"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="33.3"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Pulse Rate</title>
        <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
        <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
        <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A- Placebo</title>
            <description>Subjects received matching placebo under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O10">
            <title>Part B</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Pulse Rate</title>
          <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
          <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Trends in 12-lead Electrocardiograms</title>
        <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
        <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
        <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A- Placebo</title>
            <description>Subjects received matching placebo under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O10">
            <title>Part B</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Trends in 12-lead Electrocardiograms</title>
          <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
          <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD9977 by Number of Participants With Clinically Significant Trends in Cardiac Telemetry</title>
        <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
        <time_frame>For up to 4 days, i.e. on the day before each dosing and for 24 hours after each dosing</time_frame>
        <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A- Placebo</title>
            <description>Subjects received matching placebo under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O10">
            <title>Part B</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD9977 by Number of Participants With Clinically Significant Trends in Cardiac Telemetry</title>
          <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
          <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD9977 by Assessing the Number of Subjects With Adverse Events</title>
        <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
        <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
        <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A- Placebo</title>
            <description>Subjects received matching placebo under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O10">
            <title>Part B</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD9977 by Assessing the Number of Subjects With Adverse Events</title>
          <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
          <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Blood Pressure</title>
        <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
        <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
        <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A- Placebo</title>
            <description>Subjects received matching placebo under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O10">
            <title>Part B</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Blood Pressure</title>
          <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
          <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Hematology</title>
        <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
        <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
        <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A- Placebo</title>
            <description>Subjects received matching placebo under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O10">
            <title>Part B</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Hematology</title>
          <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
          <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Clinical Chemistry</title>
        <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
        <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
        <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A- Placebo</title>
            <description>Subjects received matching placebo under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O10">
            <title>Part B</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Clinical Chemistry</title>
          <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
          <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Urinalysis</title>
        <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
        <time_frame>For up to 45 days, i.e. from Screening to Follow-up</time_frame>
        <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A- Placebo</title>
            <description>Subjects received matching placebo under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O10">
            <title>Part B</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Urinalysis</title>
          <description>To assess the safety and tolerability of single ascending doses of AZD9977</description>
          <population>All subjects who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity.</title>
        <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
        <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
        <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Intellicap Device (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
          <group group_id="O10">
            <title>Oral Suspension (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity.</title>
          <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
          <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
          <units>h.nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="514.4" spread="13.4"/>
                    <measurement group_id="O2" value="2473" spread="24.5"/>
                    <measurement group_id="O3" value="9576" spread="51.9"/>
                    <measurement group_id="O4" value="23810" spread="33.7"/>
                    <measurement group_id="O5" value="36210" spread="28.5"/>
                    <measurement group_id="O6" value="38060" spread="37.2"/>
                    <measurement group_id="O7" value="98910" spread="29.7"/>
                    <measurement group_id="O8" value="105700" spread="30.5"/>
                    <measurement group_id="O9" value="2256" spread="32.6"/>
                    <measurement group_id="O10" value="3294" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte concentrationAUC(0-t)</title>
        <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
        <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
        <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Intellicap Device (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
          <group group_id="O10">
            <title>Oral Suspension (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte concentrationAUC(0-t)</title>
          <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
          <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
          <units>h.nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="482.7" spread="14.9"/>
                    <measurement group_id="O2" value="2429" spread="24.7"/>
                    <measurement group_id="O3" value="9419" spread="52.2"/>
                    <measurement group_id="O4" value="23470" spread="34.2"/>
                    <measurement group_id="O5" value="35650" spread="26.0"/>
                    <measurement group_id="O6" value="34190" spread="16.1"/>
                    <measurement group_id="O7" value="82720" spread="35.6"/>
                    <measurement group_id="O8" value="93750" spread="37.5"/>
                    <measurement group_id="O9" value="1754" spread="38.1"/>
                    <measurement group_id="O10" value="3136" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Concentration (Cmax)</title>
        <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
        <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
        <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Intellicap Device (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
          <group group_id="O10">
            <title>Oral Suspension (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Concentration (Cmax)</title>
          <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
          <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.6" spread="27.7"/>
                    <measurement group_id="O2" value="952.0" spread="20.9"/>
                    <measurement group_id="O3" value="3367" spread="41.3"/>
                    <measurement group_id="O4" value="5966" spread="40.6"/>
                    <measurement group_id="O5" value="7243" spread="27.7"/>
                    <measurement group_id="O6" value="7149" spread="17.2"/>
                    <measurement group_id="O7" value="14310" spread="29.1"/>
                    <measurement group_id="O8" value="16700" spread="29.2"/>
                    <measurement group_id="O9" value="161.2" spread="36.8"/>
                    <measurement group_id="O10" value="790.9" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Concentration (t Max)</title>
        <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
        <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
        <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Intellicap Device (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
          <group group_id="O10">
            <title>Oral Suspension (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (t Max)</title>
          <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
          <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
          <units>Hour (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.50" upper_limit="1.08"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.50" upper_limit="1.02"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.50" upper_limit="1.02"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.48" upper_limit="1.00"/>
                    <measurement group_id="O5" value="0.88" lower_limit="0.38" upper_limit="1.50"/>
                    <measurement group_id="O6" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O7" value="3.51" lower_limit="3.50" upper_limit="4.50"/>
                    <measurement group_id="O8" value="3.74" lower_limit="2.50" upper_limit="4.50"/>
                    <measurement group_id="O9" value="4.02" lower_limit="1.98" upper_limit="5.52"/>
                    <measurement group_id="O10" value="0.75" lower_limit="0.23" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz)</title>
        <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
        <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
        <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Intellicap Device (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
          <group group_id="O10">
            <title>Oral Suspension (Part B)</title>
          </group>
        </group_list>
        <measure>
          <title>Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz)</title>
          <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
          <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
          <units>Hour (h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.741" spread="0.1753"/>
                    <measurement group_id="O2" value="1.755" spread="0.2923"/>
                    <measurement group_id="O3" value="7.161" spread="4.397"/>
                    <measurement group_id="O4" value="10.00" spread="1.933"/>
                    <measurement group_id="O5" value="9.618" spread="3.412"/>
                    <measurement group_id="O6" value="22.99" spread="6.527"/>
                    <measurement group_id="O7" value="21.17" spread="12.18"/>
                    <measurement group_id="O8" value="21.68" spread="3.495"/>
                    <measurement group_id="O9" value="11.60" spread="6.081"/>
                    <measurement group_id="O10" value="6.145" spread="3.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F)</title>
        <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
        <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
        <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Intellicap Device (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
          <group group_id="O10">
            <title>Oral Suspension (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F)</title>
          <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
          <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.52" spread="3.391"/>
                    <measurement group_id="O2" value="25.89" spread="5.546"/>
                    <measurement group_id="O3" value="28.46" spread="11.08"/>
                    <measurement group_id="O4" value="21.84" spread="5.812"/>
                    <measurement group_id="O5" value="28.49" spread="7.392"/>
                    <measurement group_id="O6" value="54.34" spread="19.16"/>
                    <measurement group_id="O7" value="20.99" spread="6.683"/>
                    <measurement group_id="O8" value="29.38" spread="8.430"/>
                    <measurement group_id="O9" value="45.97" spread="13.03"/>
                    <measurement group_id="O10" value="31.82" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F)</title>
        <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
        <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
        <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O9">
            <title>Intellicap Device (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
          <group group_id="O10">
            <title>Oral Suspension (Part B)</title>
            <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F)</title>
          <description>To assess plasma pharmacokinetic parameters following single ascending doses of AZD977</description>
          <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.50" spread="9.724"/>
                    <measurement group_id="O2" value="64.52" spread="13.40"/>
                    <measurement group_id="O3" value="266.1" spread="180.6"/>
                    <measurement group_id="O4" value="315.8" spread="111.9"/>
                    <measurement group_id="O5" value="401.9" spread="180.0"/>
                    <measurement group_id="O6" value="1712" spread="123.7"/>
                    <measurement group_id="O7" value="652.5" spread="414.0"/>
                    <measurement group_id="O8" value="897.0" spread="210.6"/>
                    <measurement group_id="O9" value="720.1" spread="348.2"/>
                    <measurement group_id="O10" value="269.4" spread="142.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amount of Unchanged Drug Excreted Into Urine [Ae (0-48)]</title>
        <description>To assess urine pharmacokinetic parameters following single ascending doses of AZD9977</description>
        <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
        <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amount of Unchanged Drug Excreted Into Urine [Ae (0-48)]</title>
          <description>To assess urine pharmacokinetic parameters following single ascending doses of AZD9977</description>
          <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2491" spread="213.4"/>
                    <measurement group_id="O2" value="12440" spread="2818"/>
                    <measurement group_id="O3" value="59700" spread="21910"/>
                    <measurement group_id="O4" value="122800" spread="27020"/>
                    <measurement group_id="O5" value="189700" spread="46420"/>
                    <measurement group_id="O6" value="178600" spread="32530"/>
                    <measurement group_id="O7" value="428600" spread="93430"/>
                    <measurement group_id="O8" value="503400" spread="132300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction Excreted Unchanged in Urine[Fe (0-48)]</title>
        <description>To assess percentage of the total drug excreted in the urine that was unchanged following single ascending doses of AZD9977</description>
        <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
        <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction Excreted Unchanged in Urine[Fe (0-48)]</title>
          <description>To assess percentage of the total drug excreted in the urine that was unchanged following single ascending doses of AZD9977</description>
          <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.90" spread="1.705"/>
                    <measurement group_id="O2" value="19.88" spread="4.502"/>
                    <measurement group_id="O3" value="23.84" spread="8.750"/>
                    <measurement group_id="O4" value="24.53" spread="5.396"/>
                    <measurement group_id="O5" value="18.94" spread="4.635"/>
                    <measurement group_id="O6" value="8.917" spread="1.624"/>
                    <measurement group_id="O7" value="21.40" spread="4.664"/>
                    <measurement group_id="O8" value="16.75" spread="4.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance of Drug From Plasma [CLR (0-48)]</title>
        <description>To assess urine pharmacokinetic parameters following single ascending doses of AZD9977</description>
        <time_frame>Pre-dose and post-dose upto 48 hrs</time_frame>
        <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 5 mg AZD9977</title>
            <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Part A - 25 mg AZD9977</title>
            <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Part A - 100 mg AZD9977</title>
            <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O4">
            <title>Part A - 200 mg AZD9977</title>
            <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400 mg AZD9977</title>
            <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800 mg AZD9977</title>
            <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
            <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance of Drug From Plasma [CLR (0-48)]</title>
          <description>To assess urine pharmacokinetic parameters following single ascending doses of AZD9977</description>
          <population>The PK analysis set for Part A consisted of all subjects in the safety analysis set who received one dose of AZD9977 and had evaluable PK data. The PK analysis set for Part B consisted of all subjects in the safety analysis set who received at least one dose of AZD9977 and had evaluable PK data in at least one period.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.018" spread="0.5818"/>
                    <measurement group_id="O2" value="5.061" spread="1.195"/>
                    <measurement group_id="O3" value="6.114" spread="1.533"/>
                    <measurement group_id="O4" value="5.230" spread="1.028"/>
                    <measurement group_id="O5" value="5.371" spread="0.6880"/>
                    <measurement group_id="O6" value="5.700" spread="1.097"/>
                    <measurement group_id="O7" value="5.274" spread="0.9817"/>
                    <measurement group_id="O8" value="5.319" spread="0.5086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs will be collected from the signing of informed consent and AEs from randomization until the final follow-up visit in Part A, and from first dosing until the final follow-up visit in Part B.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A- Placebo</title>
          <description>Subjects received matching placebo under fasted conditions</description>
        </group>
        <group group_id="E2">
          <title>Part A - 5 mg AZD9977</title>
          <description>Subjects received 5 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="E3">
          <title>Part A - 25 mg AZD9977</title>
          <description>Subjects received 25 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="E4">
          <title>Part A - 100 mg AZD9977</title>
          <description>Subjects received 100 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="E5">
          <title>Part A - 200 mg AZD9977</title>
          <description>Subjects received 200 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="E6">
          <title>Part A - 400 mg AZD9977</title>
          <description>Subjects received 400 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="E7">
          <title>Part A - 800 mg AZD9977</title>
          <description>Subjects received 800 mg AZD9977, oral suspension under fasted conditions</description>
        </group>
        <group group_id="E8">
          <title>Part A - 800 mg AZD9977 (Split Doses)</title>
          <description>Subjects received 800 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
        </group>
        <group group_id="E9">
          <title>Part A - 1200 mg AZD9977 (Split Doses)</title>
          <description>Subjects received 1200 mg AZD9977 (split doses), oral suspension under fasted conditions</description>
        </group>
        <group group_id="E10">
          <title>Part B</title>
          <description>Subjects received a single dose of AZD9977, under fasted conditions, on two occasions (40 mg AZD9977, IntelliCap device and 40 mg AZD9977, oral solution) separated by a washout period of at least 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Feces soft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Backpain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia intercostal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Leader</name_or_title>
      <organization>AstraZeneca AB</organization>
      <phone>+46 31 7761000</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

